Bicara Therapeutics SEC Filings

BCAX insider Ryan Cohlhepp filed a Rule 144 notice to sell 149 shares of the company’s common stock through UBS Financial Services on or around 01/15/2026, with an aggregate market value of $2,684.98. The filing reports that these shares were acquired on 05/12/2024 by exercising a stock option for cash. The notice indicates total common shares outstanding of 54,781,950, showing this planned sale is very small relative to the company’s share base.

Over the prior three months, Cohlhepp sold additional common shares in three equal blocks of 12,500 shares each on 10/15/2025, 11/21/2025, and 12/15/2025, with reported gross proceeds of $226,942.50, $225,587.50, and $233,547.50, respectively. The signer represents that he does not know of any undisclosed material adverse information about BCAX at the time of this notice.

Bicara Therapeutics Inc. filed a Form 8-K to report that it issued a press release on January 12, 2026 titled “Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook.”

The company states that this press release is furnished as Exhibit 99.1 and incorporated by reference, indicating it contains details on the chosen Phase 3 dose and management’s outlook for 2026.

Bicara Therapeutics Inc. disclosed that its Chief Executive Officer and director exercised stock options and acquired common shares. On 12/16/2025, the reporting person exercised a stock option and acquired 29,500 shares of common stock at an exercise price of $5.4537 per share. After this transaction, the reporting person beneficially owned 339,392 shares of common stock directly.

The exercised option was part of a larger grant of stock options with an exercise price of $5.4537, originally covering shares of common stock and expiring on 12/14/2033. Following the reported transaction, the reporting person held 565,512 stock options directly. The option grant vests in sixteen equal quarterly installments following December 14, 2023, subject to the reporting person’s continued service.

Bicara Therapeutics reported insider transactions by its President and COO, who is also a director. On December 15, 2025, the insider exercised stock options for 8,000 shares of common stock at an exercise price of $3.7898 per share and, in separate trades, sold 8,000 and 4,500 shares of common stock at a weighted average price of $18.6838 per share under a Rule 10b5-1 trading plan adopted on February 12, 2025.

After these transactions, the insider directly owned 189,141 shares of Bicara common stock and held 141,334 stock options. The option covers 8,000 underlying shares in this transaction, carries a $3.7898 exercise price, expires on August 8, 2033, and vests in sixteen equal quarterly installments following August 8, 2023, subject to continued service.

Bicara Therapeutics Inc. is launching an at-the-market offering of up to $150,000,000 of its common stock through TD Securities (USA) LLC (TD Cowen) as sales agent. Shares may be sold from time to time on The Nasdaq Global Market under the symbol BCAX, in negotiated transactions or other methods deemed to be at-the-market offerings, with TD Cowen earning a commission of up to 3.0% of gross proceeds.

Bicara is a clinical-stage biopharmaceutical company focused on bifunctional antibodies for solid tumors. Its lead program, ficerafusp alfa, is in a pivotal Phase 2/3 trial in head and neck squamous cell carcinoma, following Phase 1/1b data showing a 54% objective response rate and 21.3‑month median overall survival in an efficacy-evaluable HPV‑negative population. Net proceeds are expected to support research and clinical development, commercialization preparation, expansion of R&D programs, and general corporate purposes.

Bicara Therapeutics Inc. (BCAX) reported insider transactions by its Chief Financial Officer on Form 4. On November 21, 2025, the CFO exercised 605 stock options at $3.7898 per share and sold 605 shares of common stock at a price of $18.15 per share. On November 24, 2025, the CFO exercised an additional 17,795 options at $3.7898 and sold 17,795 shares at a weighted average price of $18.5498, with sales occurring between $18.15 and $18.84. After these trades, the CFO beneficially owned 145,355 shares of common stock directly and held 98,184 stock options. The transactions were carried out under a Rule 10b5-1 trading plan adopted on February 13, 2025.

Bicara Therapeutics Inc. insider transaction: On 11/21/2025, a reporting person who is both a director and the President and COO of Bicara Therapeutics Inc. (BCAX) exercised a stock option for 8,000 shares of common stock at an exercise price of $3.7898 per share and then sold shares of common stock on the same day.

The insider reported selling 8,000 shares of common stock at a weighted average price of $18.047 per share and an additional 4,500 shares at the same weighted average price, executed in multiple trades between $18.00 and $18.14. After these transactions, the insider beneficially owned 193,641 shares of common stock directly and 149,334 stock options. The option for 8,000 shares was granted on August 8, 2023 and vests in sixteen equal quarterly installments, contingent on continued service, and was exercised under a Rule 10b5-1 trading plan adopted on February 12, 2025.

Bicara Therapeutics Inc. (BCAX)41,163 shares of common stock at an exercise price of $3.7898 per share and then sold 41,163 shares of common stock at a weighted average price of $18.8623 per share under transaction code "S".

The option exercised is a stock option (right to buy) covering 41,163 shares of common stock, with an exercise price of $3.7898, expiring on 08/08/2033. The filing states that these option shares vest in sixteen equal quarterly installments following August 8, 2023, subject to continued service. After the reported transactions, the reporting person beneficially owns 309,892 shares of common stock and 236,107 stock options, all held directly. The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.

Bicara Therapeutics Inc. (BCAX) reported insider transactions by its Chief Medical Officer, who filed a Form 4 as a single reporting person. On 11/24/2025 and 11/25/2025, the officer exercised stock options to acquire common shares at an exercise price of $3.7898 per share and sold the same number of shares on each corresponding date.

On 11/24/2025, 5,500 shares of common stock were acquired through an option exercise and 5,500 shares were sold at $18.45 per share, leaving 35,497 shares owned directly. On 11/25/2025, additional option exercises and sales covered 4,594 and 906 shares, with sales at a weighted average price of $18.8424. After these transactions, the officer directly owned 35,497 common shares and held stock options covering 69,413 shares, subject to the vesting schedules described.

The filing notes that these trades were made under a Rule 10b5-1 trading plan adopted on February 12, 2025, with certain sale prices reported as weighted averages across multiple individual transactions.